Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension

Drug Delivery

Volumn 18, Issue 4, 2011, Pages 265-271

  Feng, Fei Fei ^a   Zhang, Dian Rui ^a   Tian, Ke Li ^b   Lou, Hai Yan ^a   Qi, Xiao Li ^b   Wang, Yan Cai ^a   Duan, Cun Xian ^a   Jia, Le Jiao ^a   Wang, Fei Hu ^a   Liu, Yue ^a   Zhang, Qiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

apoptosis; MCF 7 cells; nanosuspension; Oridonin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; ORIDONIN; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIVISION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; FAR WESTERN BLOTTING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALASSEZIA PACHYDERMATIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE; HUMANS; NANOPARTICLES; PROTO-ONCOGENE PROTEINS C-BCL-2; SUSPENSIONS;

EID: 79953235959     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.536271     Document Type: Article

References (18)

1. 53 stability and activity in response to genotoxic stress. Mutat Res. 462:179-88. (Pubitemid 30190225)
2. 53-mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 28:1057-66. (Pubitemid 47020485)
3. Date, A.A., Joshi, M.D., Patravale, V.B. (2007). Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 59:505-21. (Pubitemid 47259228)
4. Eerdenbrugh, B.V., Mooter, G.V., Augustijns, P. (2008). Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 364:64-75.
5. Engblom, P., Pulkkinen, J.O., Rantanen, V., Hirvonen, H., Kulmala, J., Grènman, R., Grènman, S. (1999). Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis. Eur J Cancer. 35:284-8. (Pubitemid 29136780)
6. Gao, L., Zhang, D.R., Chen, M.H., Duan, C.X., Dai, W.T., Jia, L.J., Zhao, W.F. (2008). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspension. Int J Pharm. 355:321-7.
7. Ikezoe, T., Chen, S.S., Tong, X.J., Heber, D., Taguchi, H., Koeffler, H.P. (2003). Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 23:1187-93.
8. Kesisoglou, F., Panmai, S., Wu, Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59:631-44. (Pubitemid 47285408)
9. Liang, Y., Nylander, K.D., Yan, C., Schor, N.F. (2002). Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2. Mol Pharmacol. 61:142-9. (Pubitemid 34049521)
10. Mehnert, W., Mäder, K. (2001). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 47: 165-96. (Pubitemid 32324113)
11. Muller, R.H., Keck, C.M. (2004). Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 113:151-70. (Pubitemid 39237077)
12. Nicholson, D.W., Thornberry, N.A. (1997). Caspases, killer proteases. Trends Biochem Sci. 22:299-306.
13. Rieux, A.D., Fievez, V., Garinot, M. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Contr Rel. 116:1-27. (Pubitemid 44792295)
14. Tsujimoto, Y., Shimizu, S. (2000). Bcl-2 family: Life-or-death switch. FEBS Lett. 466:6-10. (Pubitemid 30050673)
15. Westesen, K., Bunjes, H., Koch, M.H.J. (1997). Physicochemical characterisation of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Contr Rel. 48:223-36. (Pubitemid 27401980)
16. Wong, H.L., Bendayan, R., Rauth, A.M. (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 59:491-504. (Pubitemid 47259227)
17. Wong, J., Brugger, A., Khare, A., Chaubal, M., Papadopoulos, P., Rabinow, B., Kipp, J., Ning, J. (2008). Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Deliv Rev. 60:939-54.
18. Zhang, T.M. (1982). Recent studies on the antitumor activity of rabdosia rubescences. Chin J Oncol. 4:322-3.